scholarly journals Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials

2019 ◽  
Vol 34 (5) ◽  
pp. 1050-1056 ◽  
Author(s):  
H.H. Zee ◽  
M. Longcore ◽  
Z. Geng ◽  
A. Garg
Keyword(s):  
Hidradenitis Suppurativa ◽  
Phase 3 ◽  
Disease Flare ◽  
Adalimumab Treatment

Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Cristina Garcia‐Melendo ◽  
Eva Vilarrasa ◽  
Xavier Cubiró ◽  
Flavia Bittencourt ◽  
Lluís Puig
Keyword(s):  
Hidradenitis Suppurativa ◽  
Adalimumab Treatment

scholarly journals Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
Aikaterini Kyriakou ◽  
Anastasia Trigoni ◽  
Nikiforos Galanis ◽  
Dimitrios Sotiriadis ◽  
Aikaterini Patsatsi
Keyword(s):  
Quality Of Life ◽  
Hidradenitis Suppurativa ◽  
Therapeutic Potential ◽  
Therapeutic Option ◽  
Real Life ◽  
Life Quality ◽  
Global Assessment Scale ◽  
Friedman's Test ◽  
Adalimumab Treatment

Hidradenitis suppurativa (HS) is a relapsing, inflammatory disease characterized by painful nodules, abscesses, sinuses track formation and scarring. HS has a great impact on patients’ quality of life and its treatment may be really challenging. Adalimumab provides a new therapeutic option for HS. Our aim was to assess the therapeutic potential of adalimumab on patients with HS based on the data from the daily clinical practice of an HS Outpatient Clinic. 19 patients with clinically evident moderate to severe HS, under adalimumab treatment for at least 24 week, participated in this observational, retrospective study. The Hidradenitis Suppurativa Physician’s Global Assessment scale, Modified Santorius scale and Dermatology Life Quality Index (DLQI) at baseline, week 4, week 12 and week 24 were retrieved from the records. Both Modified Santorius score and DLQI were significantly decreased during the weeks of evaluation (Friedman’s test; P < 0.001). The proportion of patients who achieved clinical response was 10.5% (n = 2) at week 4, 42.1% (n = 8) at week 12 and 63.2% (n = 12) at week 24. Treatment with adalimumab was linked with both clinical remission of HS and improvement of patients’ quality of life.

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

2019 ◽  
Vol 80 (1) ◽  
pp. 60-69.e2 ◽  
Author(s):  
Christos C. Zouboulis ◽  
Martin M. Okun ◽  
Errol P. Prens ◽  
Robert Gniadecki ◽  
Peter A. Foley ◽  
...  
Keyword(s):  
Hidradenitis Suppurativa ◽  
Extension Study ◽  
Acne Inversa ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Extension
Sign in / Sign up

Export Citation Format

Share Document